Researchers recently investigated several cognitive aging markers to understand how brain changes affect mental performance in older adults. The study examined the roles of dopamine integrity, astrocyte reactivity, and cerebral small-vessel disease (SVD). Healthy adults between the ages of 60 and 79 participated in this comprehensive neuroimaging research.

Identifying Cognitive Aging Markers

The research team utilized positron emission tomography (PET) to measure dopamine transporter levels and astrocyte activity. Additionally, they assessed white matter lesion volumes using magnetic resonance imaging (MRI). Furthermore, these cognitive aging markers provided a detailed map of age-related brain changes. Specifically, the study aimed to determine which factors most strongly predict cognitive outcomes like episodic memory and perceptual speed.

Key Study Findings and Results

Specifically, the researchers found that increased astrocyte reactivity was associated with higher dopamine transporter availability. However, higher levels of astrocyte reactivity and cerebral SVD both predicted lower cognitive performance independently. In contrast to expectations, dopamine decline was not the only significant driver of cognitive issues. Consequently, these results suggest that successful aging requires maintaining multiple brain systems. Moreover, SVD volumes appeared to affect cognition without directly impacting dopamine integrity.

Clinical Implications for Brain Health

This research highlights that clinicians should evaluate multiple factors when assessing brain health. Specifically, both vascular and glial markers play vital roles in cognitive trajectories. Identifying these markers early could lead to more personalized interventions for elderly patients. In addition, future treatments may need to target inflammation and vascular health alongside neurochemical balance.

Frequently Asked Questions

What are the primary markers of cognitive aging?

The study identifies dopamine transporter levels, astrocyte reactivity (measured by MAO-B levels), and cerebral small-vessel disease as key markers.

Can cognitive decline occur independently of dopamine loss?

Yes, research shows that astrocyte reactivity and small-vessel disease can negatively impact cognition even when dopamine levels remain relatively stable.

How was astrocyte reactivity measured in this study?

Researchers used C-L-deprenyl-D ligands in PET scans to estimate levels of monoamine oxidase B, a protein primarily expressed by astrocytes.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional opinion. Always seek the direct advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Crine V et al. The role of dopamine decline, astrocyte reactivity, and cerebral small-vessel disease in cognitive aging. J Cereb Blood Flow Metab. 2026 Apr 11. doi: 10.1177/0271678X261441065. PMID: 41964364.

Karalija N et al. Cerebral small-vessel disease severity, hypertension, and body mass index forecast striatal dopamine D2-receptor decline rates in aging. Neurobiol Aging. 2025 Dec;156:30-39.

Low A et al. Inflammation and cerebral small vessel disease: A systematic review. Ageing Res Rev. 2019;53:100916.